Free tool
FAERS Monitor: Viltepso
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212154 or its brand name (Viltepso, Viltolarsen). Reports on generic versions are filed under their own applications.
Reports
170
Serious
54
32% of reports
Hospitalization
42
Death reported
7
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia21
- vomiting14
- illness11
- weight increased9
- pneumonia8
- malaise7
- cough6
- covid-196
- product dose omission issue6
- diarrhoea5
- fall5
- influenza5
- off label use5
- sars-cov-2 test positive5
- abdominal discomfort4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 13 |
| 2022 | 19 |
| 2023 | 29 |
| 2024 | 41 |
| 2025 | 47 |
| 2026 | 20 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,989 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sars-cov-2 test positiveSignal | 5 | 46.9 | 19.8 | 181 |
| illnessSignal | 11 | 13.2 | 7.5 | 113 |
| pyrexiaSignal | 21 | 7.5 | 5.0 | 114 |
| influenzaSignal | 5 | 5.5 | 2.3 | 14 |
| weight increasedSignal | 9 | 5.0 | 2.6 | 25 |
| covid-19Signal | 6 | 4.2 | 1.9 | 12 |
| vomitingSignal | 14 | 3.7 | 2.2 | 25 |
| pneumoniaSignal | 8 | 3.1 | 1.6 | 9 |
| abdominal discomfort | 4 | 3.0 | 1.1 | 3 |
| coughSignal | 6 | 2.6 | 1.2 | 5 |
| product dose omission issueSignal | 6 | 2.5 | 1.2 | 4 |
| malaise | 7 | 2.0 | 1.0 | 3 |
| fall | 5 | 1.9 | 0.8 | 1 |
| diarrhoea | 5 | 1.0 | 0.4 | 0 |
| off label use | 5 | 0.7 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.